相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Yammy Yung et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
miRNome profiling of LSC-enriched CD34+CD38-CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool
Maria Sol Ruiz et al.
FRONTIERS IN PHARMACOLOGY (2021)
Target Inhibition of CBP Induced Cell Senescence in BCR-ABL-T315I Mutant Chronic Myeloid Leukemia
Ke Yang et al.
FRONTIERS IN ONCOLOGY (2021)
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Ya-Ching Hsieh et al.
LEUKEMIA (2021)
Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome
Mohammad Houshmand et al.
CANCERS (2021)
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1-CD44 axis
Parimala Sonika Godavarthy et al.
HAEMATOLOGICA (2020)
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells
Sofia von Palffy et al.
HAEMATOLOGICA (2020)
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
Ilaria S. Pagani et al.
LEUKEMIA (2020)
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
G. A. Horne et al.
LEUKEMIA (2020)
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
Ross Kinstrie et al.
LEUKEMIA (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia
Weiqi Huang et al.
LEUKEMIA (2020)
Treatment-free remission in patients with chronic myeloid leukaemia
David M. Ross et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response
Katia B. B. Pagnano et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Peripheral Blood CD26+Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS)
Monica Bocchia et al.
BLOOD (2020)
Targeting quiescent leukemic stem cells using second generation autophagy inhibitors
Pablo Baquero et al.
LEUKEMIA (2019)
Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells
Puneet Agarwal et al.
CELL STEM CELL (2019)
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia
Donatella Raspadori et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)
Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling
Maja Kim Kuepper et al.
LEUKEMIA (2019)
Dietary Phytochemicals Targeting Cancer Stem Cells
Alena Liskova et al.
MOLECULES (2019)
Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
Simona Soverini et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
Simona Bernardi et al.
CANCER MEDICINE (2019)
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells
Ajay Abraham et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells
Chun Shik Park et al.
BLOOD (2019)
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
Peter Valent et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
Fabien Muselli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells
Walid Warda et al.
CANCER RESEARCH (2019)
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
Luana Bavaro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
Niklas Landberg et al.
HAEMATOLOGICA (2018)
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
Niklas Landberg et al.
HAEMATOLOGICA (2018)
hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival
Francesca Pellicano et al.
BLOOD (2018)
Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia
Michael Willmann et al.
EXPERIMENTAL HEMATOLOGY (2018)
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Simona Soverini et al.
MOLECULAR CANCER (2018)
Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia
Bin Zhang et al.
NATURE MEDICINE (2018)
Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
Katharina Blatt et al.
NEOPLASIA (2018)
Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
Monica Bocchia et al.
FRONTIERS IN ONCOLOGY (2018)
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
Kendra Sweet et al.
LEUKEMIA RESEARCH (2018)
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
Philippe Rousselot et al.
CANCER (2017)
Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications
Irina Sadovnik et al.
EXPERIMENTAL HEMATOLOGY (2017)
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Elodie M. Kuntz et al.
NATURE MEDICINE (2017)
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia
Alice Giustacchini et al.
NATURE MEDICINE (2017)
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells
Simona Salati et al.
ONCOTARGET (2017)
Immature CML cells implement a BMP autocrine loop to escape TKI treatment
Elodie Grockowiak et al.
BLOOD (2017)
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
Rebecca Warfvinge et al.
BLOOD (2017)
Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML
Irina Sadovnik et al.
CLINICAL CANCER RESEARCH (2016)
IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome
N. Landberg et al.
LEUKEMIA (2016)
CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells
Y. Zhao et al.
ONCOGENE (2016)
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells
Bin Zhang et al.
BLOOD (2016)
ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis
Maria Anna Zipeto et al.
CELL STEM CELL (2016)
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy
Noortje Thielen et al.
CLINICAL CANCER RESEARCH (2016)
Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells
Bin Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
Sheela A. Abraham et al.
NATURE (2016)
Best Practices in Chronic Myeloid Leukemia Monitoring and Management
Simona Soverini et al.
ONCOLOGIST (2016)
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Bing Z. Carter et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
Mary T. Scott et al.
CANCER DISCOVERY (2016)
Quantitative assessment of the CD26+leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects
Martin Culen et al.
ONCOTARGET (2016)
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
Jean Claude Chomel et al.
ONCOTARGET (2016)
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
David A. Irvine et al.
SCIENTIFIC REPORTS (2016)
Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia
Ross Kinstrie et al.
BLOOD ADVANCES (2016)
Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC
Irina Sadovnik et al.
BLOOD (2016)
Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development
Marisa Bowers et al.
BLOOD (2015)
Phytochemicals as Innovative Therapeutic Tools against Cancer Stem Cells
Emanuele-Salvatore Scarpa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway
Wei-Zhang Wang et al.
LEUKEMIA RESEARCH (2015)
Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling
Carsten Riether et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
A. M. Eiring et al.
LEUKEMIA (2015)
CD93 Is a Novel Biomarker of Leukemia Stem Cells in Chronic Myeloid Leukemia
Ross Kinstrie et al.
BLOOD (2015)
Fenretinide Targets Chronic Myeloid Leukemia Stem/Progenitor Cells by Regulation of Redox Signaling
Yanzhi Du et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche
Daniela S. Krause et al.
BLOOD (2014)
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
Harald Herrmann et al.
BLOOD (2014)
The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells
Chiharu I. Kobayashi et al.
BLOOD (2014)
Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors
Edward J. Wu et al.
CANCER BIOLOGY & THERAPY (2014)
DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia
Peter Valent et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2014)
Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
Yaoyu Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Complete Cytogenetic Response, Not Deep Molecular Response, Is Associated With Survival in Chronic Myeloid Leukemia
Hagop Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Molecular Monitoring
Simona Soverini et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression
Bastien Laperrousaz et al.
BLOOD (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation
Paolo Gallipoli et al.
BLOOD (2013)
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling
Bin Zhang et al.
BLOOD (2013)
A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
Daniel J. Goff et al.
CELL STEM CELL (2013)
Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval
Hagop M. Kantarjian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Paolo Neviani et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1BCR-ABL-JAK2 Complex
Min Chen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
S. Mustjoki et al.
LEUKEMIA (2013)
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis
Hongfeng Yuan et al.
BLOOD (2012)
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Ashley Hamilton et al.
BLOOD (2012)
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib
Ashu Kumari et al.
BLOOD (2012)
CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine
Ying Gu et al.
BLOOD (2012)
HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells
Haojian Zhang et al.
BLOOD (2012)
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
Ling Li et al.
CANCER CELL (2012)
Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
Bin Zhang et al.
CANCER CELL (2012)
CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression
Christian Schuerch et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib
J. J. W. M. Janssen et al.
LEUKEMIA (2012)
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
E. Traer et al.
LEUKEMIA (2012)
Autophagy modulation as a potential therapeutic target for diverse diseases
David C. Rubinsztein et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
Su Chu et al.
BLOOD (2011)
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
Jean-Claude Chomel et al.
BLOOD (2011)
Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic Niche
Toshio Suda et al.
CELL STEM CELL (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance
Monika Mortensen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
Bin Zhang et al.
CANCER CELL (2010)
Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl
Mark A. Gregory et al.
CANCER CELL (2010)
The Distinct Metabolic Profile of Hematopoietic Stem Cells Reflects Their Location in a Hypoxic Niche
Tugba Simsek et al.
CELL STEM CELL (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy
S. Mustjoki et al.
LEUKEMIA (2010)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
D. M. Ross et al.
LEUKEMIA (2010)
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka et al.
NATURE (2010)
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein
Marcus Jaras et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
Cristian Bellodi et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells
Duncan H. Mak et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Chen Zhao et al.
NATURE (2009)
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
Yaoyu Chen et al.
NATURE GENETICS (2009)
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation
Christine Dierks et al.
CANCER CELL (2008)
Imatinib mesylate for the treatment of chronic myeloid leukemia
Simona Soverini et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
PML targeting eradicates quiescent leukaemia-initiating cells
Keisuke Ito et al.
NATURE (2008)
Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo
Chen Zhao et al.
CANCER CELL (2007)
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells
Hardik Modi et al.
BLOOD (2007)
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells
Daniela S. Krause et al.
NATURE MEDICINE (2006)
PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR
Rosa Bernardi et al.
NATURE (2006)
Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease
W Eisterer et al.
LEUKEMIA (2005)
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
R Bhatia et al.
BLOOD (2003)
A role for Wnt signalling in self-renewal of haematopoietic stem cells
T Reya et al.
NATURE (2003)
The role of PML in tumor suppression
P Salomoni et al.
CELL (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
分享论文
